Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 11/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623481 | 1.00 | GABRA1 (0.49) | GABRA1GABRB2GABRG2GABRB3GABRA3 | |
| SCHEMBL11279073 | 0.77 | NPC1 (0.59) | PYGLITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL11279078 | 0.77 | NPC1 (0.59) | PYGLITGB2ICAM1ITGALSIGMAR1 | |
| SCHEMBL7622126 | 0.74 | CYP1A2 (0.54) | PYGLITGB2ICAM1ITGALPTGS2 | |
| SCHEMBL7622123 | 0.74 | CYP1A2 (0.54) | PYGLITGB2ICAM1ITGALPTGS2 | |
| SCHEMBL11464283 | 0.71 | ALDH1A1 (0.58) | PYGLPTGS2 | |
| SCHEMBL12488307 | 0.70 | GABRA1 (0.64) | GABRA1GABRB2GABRG2GABRB3GABRA3 | |
| SCHEMBL9029541 | 0.70 | SIGMAR1 (0.47) | PYGLSIGMAR1PTGS2 | |
| SCHEMBL9029549 | 0.70 | SIGMAR1 (0.47) | PYGLSIGMAR1PTGS2 | |
| SCHEMBL9029533 | 0.70 | SIGMAR1 (0.47) | PYGLSIGMAR1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6458806-B1 | ANTIINFLAMMATORY AND -ARTHRITIC AGENTS, ATHEROSCLEROSIS, RESTENOSIS; TRANSPLANT REJECTION; INFLAMMATORY BOWEL DISEASES, CROHN'S DISEASE, ANTIALLERGENS; IMMUNE, SKIN GASTROINTESTINAL AND RESPIRATORY SYSTEM DIORDERS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-01 | — | — | US | disclosed |
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028833-A1 | ARYL ALKENAMIDES DERIVATIVES AS MCP-1 ANTAGONISTS | CCR2, CCR1, MSR1 | GABRA1 1395/4885GABRB2 1730/4885GABRG2 2763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.